NeuroPace (NPCE) announced the presentation at the American Epilepsy Society meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS trial evaluating the RNS System as an adjunctive therapy for the treatment of antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic-clonic seizures. At 18 months of therapy, patients treated with the RNS System experienced a 77% median reduction in GTC seizures compared with baseline. Reductions in GTCs and days without any generalized seizure were rapid and sustained over time. The benefits of treatment were strongly endorsed by physicians and patients with Clinical Global Impression of Change exceeding 80% in both groups at 18 months. Safety results were consistent with the well-established RNS System profile and demonstrated significant outcomes.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NeuroPace announces Medicare reimbursement increases for RNS System
- NeuroPace’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- NeuroPace, Inc. Reports Record Revenue and Growth
- NeuroPace price target raised to $18 from $16 at JPMorgan
- NeuroPace Reports Record Revenue and Raises Guidance